AMN医疗保健服务公司 AMN 深 沪
等待开盘 12-23 09:30:00 美东时间
15.89
-0.150
-0.94%
华盛通- 最 高16.29
- 今 开16.00
- 成交量 86.11万股
- 最 低 15.80
- 昨 收 16.04
- 总市值 6.09亿
- 52周最高 30.49
- 市盈率 静 --
- 换手率 2.25%
- 52周最低 14.865
- 委 比 -23.08%
- 总股本 3832.43万
- 历史最高 129.12
- 量 比 0.72
- 振 幅 3.05%
- 历史最低 14.865
- 每 手 1
- 风险率 3.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
12-22 15:05
Citizens Maintains Market Outperform on AMN Healthcare Services, Lowers Price Target to $22
Citizens analyst Constantine Davides maintains AMN Healthcare Services (NYSE:AMN) with a Market Outperform and lowers the price target from $24 to $22.
12-19 21:29
AI Pushes Magnificent 7 Into A 'War Of The Seven Kings,' Ed Yardeni Warns
Ed Yardeni says AI is forcing Big Tech into a costly "War of the Seven Kings" that could reshape competition and returns.
12-15 23:45
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Citizens Maintains Market Outperform on AMN Healthcare Services, Raises Price Target to $24
Citizens analyst Constantine Davides maintains AMN Healthcare Services (NYSE:AMN) with a Market Outperform and raises the price target from $22 to $24.
11-07 21:39
AMN Healthcare Services Sees Q4 Sales $715.000M-$730.000M vs $621.339M Est
AMN Healthcare Services (NYSE:AMN) sees Q4 sales of $715.000 million-$730.000 million vs $621.339 million analyst estimate.
11-07 05:32
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
Analyst Expectations For AMN Healthcare Services's Future
4 analysts have expressed a variety of opinions on AMN Healthcare Services (NYS...
10-14 05:01
